Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
February 27 2017 - 7:00AM
Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage
biopharmaceutical company focused on developing entinostat and
SNDX-6352 in multiple cancer indications, today announced its
planned participation in three upcoming investor conferences. The
details for the three conferences are:
- The Cowen and Company 37th Annual Health Care
Conference at the Boston Marriott Copley Place on March 6,
2017. Briggs W. Morrison, M.D., Chief Executive Officer of
Syndax, will make a presentation at 3:20 pm ET.
- The 29th Annual ROTH Conference at the Ritz Carlton
Hotel in Orange County, California on March 13, 2017.
Michael A. Metzger, President and Chief Operating Officer of
Syndax, will make a presentation at 4:30 pm PT.
- The Oppenheimer 27th Annual Healthcare Conference at
the Westin New York Grand Central on March 22, 2017.
Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will
make a presentation at 10:20 am ET.
A live webcast of these presentations can be
accessed from the Investor section of the Company's website
at www.syndax.com, where a replay of the events will also be
available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical
company focused on developing an innovative pipeline of combination
therapies in multiple cancer indications. Our lead product
candidate, entinostat, which was granted Breakthrough Therapy
designation by the FDA following positive results from our Phase 2b
clinical trial, ENCORE 301, is currently being evaluated in a Phase
3 clinical trial for advanced hormone receptor positive, human
epidermal growth factor receptor 2 negative breast cancer. Syndax
is developing entinostat, which has direct effects on both cancer
cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R
monoclonal antibody, to enhance the body's immune response on
tumors that have shown sensitivity to immunotherapy. Entinostat is
being evaluated as a combination therapeutic in Phase 1b/2 clinical
trials with Merck & Co., Inc. for non-small cell lung cancer
and melanoma; with Genentech, Inc. for TNBC; and with Pfizer Inc.
and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352
is being evaluated in a single ascending dose Phase 1 clinical
trial and is expected to be developed to treat a variety of
cancers. For more information on Syndax, please
visit www.syndax.com.
Investor Contacts
Heather Savelle
Argot Partners
heather@argotpartners.com
Tel 646.395.3734
Media Contact
Eliza Schleifstein
Argot Partners
eliza@argotpartners.com
Tel 973.361.1546
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Apr 2023 to Apr 2024